FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3131230249> ?p ?o ?g. }

• W3131230249 abstract "Randomized clinical trials showed that bortezomib, in addition to conventional chemotherapy, improves survival and disease progression in multiple myeloma (MM) patients not eligible for stem cell transplantation. The aim of this retrospective population-based cohort study is the evaluation of both clinical and economic profile of bortezomib-based versus conventional chemotherapy in daily clinical practice.Healthcare utilization databases of six Italian regions were used to identify adult patients with non-transplant MM, who started a first-line therapy with bortezomib-based or conventional chemotherapy. Patients were matched by propensity score and were followed from treatment start until death, lost to follow-up or study end-point. Overall survival (OS) and restricted mean survival time (RMST) were estimated using the Kaplan-Meier method. Association between first-line treatment and risk of death was estimated by a conditional Cox proportional regression model. Average mean cumulative costs were estimated and compared between groups.In the period 2010-2016, 3509 non-transplant MM patients met the inclusion criteria, of which 1157 treated with bortezomib-based therapy were matched to 1826 treated with conventional chemotherapy. Median OS and RMST were 33.9 and 27.9 months, and 42.9 and 38.4 months, respectively, in the two treatment arms. Overall, these values corresponded to a HR of death of 0.79 (95% CI 0.71-0.89) over a time horizon of 84 months. Average cumulative cost were 83,839 € and 54,499 €, respectively, corresponding to an incremental cost-effectiveness ratio of 54,333 € per year of life gained, a cost coherent with the willingness-to-pay thresholds frequently adopted from Western countries.These data suggested that, in a large cohort of non-transplant MM patients treated outside the experimental setting, first-line treatment with bortezomib-based therapy was associated with a favourable effectiveness and cost-effectiveness profile." @default.
• W3131230249 created "2021-03-01" @default.
• W3131230249 creator A5008985086 @default.
• W3131230249 creator A5009381933 @default.
• W3131230249 creator A5022257735 @default.
• W3131230249 creator A5026778720 @default.
• W3131230249 creator A5037790993 @default.
• W3131230249 creator A5040440696 @default.
• W3131230249 creator A5045075334 @default.
• W3131230249 creator A5045604790 @default.
• W3131230249 creator A5065864385 @default.
• W3131230249 creator A5066609948 @default.
• W3131230249 creator A5086694069 @default.
• W3131230249 creator A5090912200 @default.
• W3131230249 date "2021-01-01" @default.
• W3131230249 modified "2023-10-14" @default.
• W3131230249 title "Bortezomib-based therapy in non-transplant multiple myeloma patients: a retrospective cohort study from the FABIO project" @default.
• W3131230249 cites W1761464837 @default.
• W3131230249 cites W1867182292 @default.
• W3131230249 cites W1894101563 @default.
• W3131230249 cites W1982967337 @default.
• W3131230249 cites W1995517770 @default.
• W3131230249 cites W2038715514 @default.
• W3131230249 cites W2072237777 @default.
• W3131230249 cites W2095255742 @default.
• W3131230249 cites W2096207943 @default.
• W3131230249 cites W2102591890 @default.
• W3131230249 cites W2103289287 @default.
• W3131230249 cites W2125435699 @default.
• W3131230249 cites W2158106888 @default.
• W3131230249 cites W2244737927 @default.
• W3131230249 cites W2269371059 @default.
• W3131230249 cites W2315123323 @default.
• W3131230249 cites W2346242965 @default.
• W3131230249 cites W2425909334 @default.
• W3131230249 cites W2524132619 @default.
• W3131230249 cites W2753244592 @default.
• W3131230249 cites W2772557263 @default.
• W3131230249 cites W2887279750 @default.
• W3131230249 cites W2907261593 @default.
• W3131230249 cites W2908265631 @default.
• W3131230249 cites W2966433679 @default.
• W3131230249 cites W3014485921 @default.
• W3131230249 cites W3145716452 @default.
• W3131230249 doi "https://doi.org/10.1177/2040620721996488" @default.
• W3131230249 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7905486" @default.
• W3131230249 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33747423" @default.
• W3131230249 hasPublicationYear "2021" @default.
• W3131230249 type Work @default.
• W3131230249 sameAs 3131230249 @default.
• W3131230249 citedByCount "2" @default.
• W3131230249 countsByYear W31312302492022 @default.
• W3131230249 countsByYear W31312302492023 @default.
• W3131230249 crossrefType "journal-article" @default.
• W3131230249 hasAuthorship W3131230249A5008985086 @default.
• W3131230249 hasAuthorship W3131230249A5009381933 @default.
• W3131230249 hasAuthorship W3131230249A5022257735 @default.
• W3131230249 hasAuthorship W3131230249A5026778720 @default.
• W3131230249 hasAuthorship W3131230249A5037790993 @default.
• W3131230249 hasAuthorship W3131230249A5040440696 @default.
• W3131230249 hasAuthorship W3131230249A5045075334 @default.
• W3131230249 hasAuthorship W3131230249A5045604790 @default.
• W3131230249 hasAuthorship W3131230249A5065864385 @default.
• W3131230249 hasAuthorship W3131230249A5066609948 @default.
• W3131230249 hasAuthorship W3131230249A5086694069 @default.
• W3131230249 hasAuthorship W3131230249A5090912200 @default.
• W3131230249 hasBestOaLocation W31312302491 @default.
• W3131230249 hasConcept C126322002 @default.
• W3131230249 hasConcept C141071460 @default.
• W3131230249 hasConcept C143998085 @default.
• W3131230249 hasConcept C167135981 @default.
• W3131230249 hasConcept C2776364478 @default.
• W3131230249 hasConcept C2777478702 @default.
• W3131230249 hasConcept C2908647359 @default.
• W3131230249 hasConcept C2911091166 @default.
• W3131230249 hasConcept C50382708 @default.
• W3131230249 hasConcept C71924100 @default.
• W3131230249 hasConcept C72563966 @default.
• W3131230249 hasConcept C99454951 @default.
• W3131230249 hasConceptScore W3131230249C126322002 @default.
• W3131230249 hasConceptScore W3131230249C141071460 @default.
• W3131230249 hasConceptScore W3131230249C143998085 @default.
• W3131230249 hasConceptScore W3131230249C167135981 @default.
• W3131230249 hasConceptScore W3131230249C2776364478 @default.
• W3131230249 hasConceptScore W3131230249C2777478702 @default.
• W3131230249 hasConceptScore W3131230249C2908647359 @default.
• W3131230249 hasConceptScore W3131230249C2911091166 @default.
• W3131230249 hasConceptScore W3131230249C50382708 @default.
• W3131230249 hasConceptScore W3131230249C71924100 @default.
• W3131230249 hasConceptScore W3131230249C72563966 @default.
• W3131230249 hasConceptScore W3131230249C99454951 @default.
• W3131230249 hasFunder F4320326069 @default.
• W3131230249 hasFunder F4320334846 @default.
• W3131230249 hasLocation W31312302491 @default.
• W3131230249 hasLocation W31312302492 @default.
• W3131230249 hasLocation W31312302493 @default.
• W3131230249 hasLocation W31312302494 @default.
• W3131230249 hasOpenAccess W3131230249 @default.
• W3131230249 hasPrimaryLocation W31312302491 @default.
• W3131230249 hasRelatedWork W13505963 @default.

• next